SINGLE-CLOSURE Trial Puts Access-Site Closure Strategy Under the Microscope After TAVR
Transfemoral aortic valve replacement has become the dominant route for transcatheter valve therapy, but the procedure still depends on a deceptively fragile final step: closing a large-bore arterial access site without bleeding, dissection, stenosis, or delayed vascular injury. The SINGLE-CLOSURE Trial directly addresses that problem by comparing single versus double ProGlide devices for access-site closure after transfemoral aortic valve replacement.
The question is clinically important because closure technique is not a minor technical preference. The femoral artery must recover from a large sheath, anticoagulation is common, and many patients undergoing TAVR already carry heavy vascular burden from age, calcification, peripheral arterial disease, diabetes, or prior catheter-based procedures. A closure system that works reliably with one device could reduce procedure complexity, device use, and possibly manipulation at the puncture site. A closure strategy that needs two devices to ensure hemostasis may provide a margin of safety in difficult anatomy, but it can also add steps and introduce its own failure modes.
Why Closure Strategy Still Matters in Transfemoral Valve Therapy
Vascular access remains one of the most consequential parts of TAVR. Even when the valve implant itself is successful, the day can turn clinically difficult if the arteriotomy bleeds, the vessel narrows, or closure fails and requires bailout therapy. In practical terms, the final minutes of the procedure can determine whether recovery is routine or complicated by hematoma, transfusion, prolonged monitoring, repeat imaging, or vascular intervention.
ProGlide-based closure is widely used in large-bore femoral access because it offers a percutaneous path to sealing the artery without surgical cutdown. The tradeoff lies in how much redundancy is necessary. One device may be enough in favorable anatomy with precise puncture placement, while a second suture-mediated device might improve closure security when vessel caliber, calcification, sheath size, or puncture depth make hemostasis less predictable. The trial title signals that investigators are testing whether a simpler strategy can stand up to a more established dual-device approach in the setting of transfemoral aortic intervention.
The Trial Question Is Small in Appearance and Large in Bedside Consequence
A closure decision made in seconds can shape the next several hours of care. When bleeding is controlled cleanly, patients can often move through post-procedure recovery with fewer interruptions and less escalation of monitoring. When closure is imperfect, the downstream effect reaches beyond the groin: hemodynamic instability, nursing workload, diagnostic imaging, and occasionally vascular surgery become part of the clinical course.
The appeal of a single-device strategy is easy to understand. It could simplify workflow and reduce hardware use without sacrificing hemostasis. The counterargument is just as straightforward: large-bore arterial access after TAVR is not an ordinary puncture, and the consequences of a marginal seal can be immediate. In that setting, the choice between one and two ProGlide devices becomes a test of procedural efficiency against procedural security.
A Trial Named for a Narrow Question in a High-Stakes Procedure
The title alone places the study in a very specific niche: post-TAVR access-site closure using ProGlide devices. Even without endpoint details in the available abstract text, the trial itself reflects how TAVR has matured. The field has already moved beyond the binary question of whether transfemoral valve replacement is feasible. The active questions now live in the procedural margins—how to reduce complications, how to standardize closure, and how to preserve the safety profile of a therapy that reaches increasingly older and more vasculopathic patients.
At the bedside, the answer matters most for operators and structural heart teams that handle large-bore femoral access every day. Closure failures do not only represent technical inconvenience; they can force changes in post-procedure antithrombotic management, prolong observation, and complicate discharge planning. If a single ProGlide device proves sufficient in a defined population, the implications extend to cath lab efficiency and patient throughput. If double-device closure remains superior, the finding would reinforce a more conservative standard in a setting where a missed bleed can become a significant vascular event.
What Clinicians Will Look for in the Full Report
The practical value of the SINGLE-CLOSURE Trial will rest on how investigators define closure success and how they separate minor groin issues from events that alter care. In a transfemoral valve population, even modest differences in access-site performance can matter because the baseline risk is already concentrated in a vulnerable vascular bed. Calcified iliac and femoral vessels, tortuous anatomy, and the size of contemporary delivery systems all raise the stakes.
Clinicians reading the complete trial report will want to know whether the study supports simplification without a penalty in bleeding, whether dual-device use offers a measurable safety advantage, and whether any differences emerge in need for bailout closure or additional vascular procedures. They will also be looking for the anatomy and procedural conditions under which one strategy may be adequate and another may remain preferable. Those are not academic distinctions; they determine how a structural heart team closes the case after the valve is in place.
The title of the study is concise, but the underlying issue is not. Large-bore femoral closure after TAVR remains one of the most practical determinants of whether a transcatheter procedure ends cleanly or turns into a vascular complication.
A Procedural Question with Immediate Relevance
For now, the available abstract text identifies the comparison, not the outcome. Even so, the trial sits squarely in a part of TAVR practice where small technical choices can have outsized consequences. Single-device closure promises simplicity. Double-device closure promises redundancy. The value of the SINGLE-CLOSURE Trial will lie in determining which of those instincts better fits the demands of transfemoral aortic valve replacement, where the final stitch often decides the quality of the recovery.